Results 101 to 110 of about 15,755 (201)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior, Volume 16, Issue 5, May 2026.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
wiley   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

HASH(0x563d442697c0) [PDF]

, 2016
HASH(0x563d4416ce80)HASH ...
Grössmann, N.
core  

Elranatamab: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Pooneh Soltantabar, Hoi‐Kei Lon, Kamrine Poels, Blerta Shtylla, Donald Irby, Kristin Bompiani‐Myers, Thomas O'Brien, Jennifer Hibma   +10 more
wiley   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, Volume 116, Issue 5, Page 577-584, May 2026.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles.
Sophieke Lems, Megan Grace Mazzei, Amanda C. Foks, Coleen A. McNamara   +3 more
wiley   +1 more source

DARATUMUMAB: REVISÃO DA ATUAÇÃO E INTERFERÊNCIA NOS TESTES PRÉ- TRANSFUSIONAIS EM PACIENTES COM DIAGNOSTICO DE MIELOMA MÚLTIPLO

Hematology, Transfusion and Cell Therapy
Objetivo: Discutir a interferência da medicação Daratumumab nos testes pré-transfusionais em amostras de pacientes diagnosticados com Mieloma Múltiplo que necessitam de transfusões sanguíneas.
GN Leôncio
doaj   +1 more source

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma:CASSIOPEIA minimal residual disease results [PDF]

Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with ...
Borgsten, Fredrik, Broijl, Annemiek, Béné, Marie C., Cabarrou, Bastien, Caillot, Denis, Carson, Robin, Corre, Jill, de Boer, Carla, Dejoie, Thomas, Delforge, Michel, Facon, Thierry, Filleron, Thomas, Hebraud, Benjamin, Hua, Winnie, Hulin, Cyrille, Krevvata, Maria, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Mahéo, Sabrina, Moreau, Philippe, Perrot, Aurore, Rowe, Melissa, Sonneveld, Pieter, Tuozzo, Alba, van de Donk, Niels W.C.J., Vanquickelberghe, Véronique, Vincent, Laure, Wang, Jianping, Wuilleme, Soraya, Zweegman, Sonja   +30 more
core   +1 more source

Pretransfusion Testing and Daratumumab: Assessing Interference Risks and Developing Solutions

Global Journal of Transfusion Medicine
Daratumumab is a monoclonal antibody; anti-CD38 is used for the treatment of multiple myeloma and other hematological disorders. Daratumumab, binds to CD 38 on red blood cells (RBCs), interfering with pretransfusion testing. This interference can lead to
Saroj Rajput, Tathagata Chatterjee, Rahul Bhargava, Sanjay Rai   +3 more
doaj   +1 more source